Profile data is unavailable for this security.
About the company
Neimeth International Pharmaceuticals Plc is a Nigeria-based company, which is engaged in the manufacturing and marketing of pharmaceuticals and animal health products. The Company operates through two segments: Pharmaceuticals product group and Animal health product group. Pharmaceuticals product group is engaged in the marketing and sales of the Company's branded products and the products under the consumer product group. Animal health product group is engaged in the marketing and sales of poultry and animal range of anthelmintics, as well as production medicaments. Its products include Ethical Products, Veterinary Products, and Healthcare Products. Its Ethical Products include Ciklavit, Flucosyd, Amlovar, Norduet, and Normoretic, among others. Veterinary Products include Neimeth Piperazine, Neimycin Chick powder, and Neiva Stress. Its Healthcare Products include Antimal, Homtamin G, Urah, and Pancemol, among others. The Company operates in two geographic regions: Nigeria and Ghana.
- Revenue in NGN (TTM)2.91bn
- Net income in NGN-2.21bn
- Incorporated1991
- Employees202.00
- LocationNeimeth International Pharmaceuticals PLC1 Henry Carr StreetIkeja Industrial Estate, IkejaLAGOS NigeriaNGA
- Phone+234 9 032543202
- Fax+234 14963866
- Websitehttps://www.neimethplc.com.ng/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CYANOTECH CORP | 39.39bn | -8.43bn | 8.05bn | 77.00 | -- | 0.4563 | -- | 0.2045 | -0.7549 | -0.7549 | 3.56 | 1.53 | 0.8895 | 2.05 | 12.12 | 309,389.60 | -19.04 | -3.46 | -29.60 | -4.46 | 24.72 | 34.54 | -21.41 | -3.58 | 0.3354 | -6.61 | 0.377 | -- | -0.4616 | -5.24 | -53.11 | -- | -6.42 | -- |
| AgriFORCE Growing Systems Ltd | 95.23m | -24.88bn | 8.11bn | 7.00 | -- | 0.3873 | -- | 85.17 | -5.81 | -5.81 | 0.0037 | 0.1343 | 0.0034 | -- | 1.21 | 8,228.57 | -88.79 | -78.95 | -124.14 | -109.86 | 17.86 | -- | -26,121.49 | -243,182.50 | 1.24 | -1.28 | 0.0789 | -- | -- | -- | 8.85 | -- | 48.61 | -- |
| Vivimed Labs Ltd | 29.16bn | -62.62bn | 8.12bn | 607.00 | -- | -- | -- | 0.2783 | -38.77 | -38.77 | 17.88 | -- | -- | -- | -- | 2,429,737.00 | -- | -5.92 | -- | -8.97 | -62.46 | 33.74 | -214.73 | -14.20 | -- | -6.31 | -- | -- | -21.15 | -30.83 | -385.64 | -- | -- | -- |
| Epsilon Healthcare Ltd | 8.14bn | -6.69bn | 8.13bn | -- | -- | 0.7868 | -- | 0.9994 | -0.0198 | -0.0198 | 0.0241 | 0.0305 | 0.3839 | 17.94 | 2.73 | -- | -31.54 | -35.68 | -46.30 | -41.11 | 37.99 | 26.88 | -82.17 | -197.56 | 0.5237 | -9.28 | 0.2329 | -- | 29.36 | 30.99 | -43.77 | -- | 8.14 | -- |
| Neimeth International Pharmaceuticls PLC | 2.91bn | -2.21bn | 8.80bn | 202.00 | -- | 5.28 | -- | 3.03 | -0.5165 | -0.5165 | 0.691 | 0.3903 | 0.3063 | 0.6875 | 2.54 | 14,400,220.00 | -23.32 | -- | -54.74 | -- | 47.01 | -- | -76.13 | -- | 0.4043 | 0.035 | 0.7161 | -- | -- | -- | -- | -- | -- | -- |
| Stemtech Corp | 8.88bn | -8.45bn | 9.05bn | 45.00 | -- | -- | -- | 1.02 | -0.0518 | -0.0518 | 0.0529 | -0.0359 | 1.33 | 8.39 | 42.31 | -- | -126.26 | -- | -- | -- | 77.87 | -- | -95.16 | -- | 0.065 | -2.59 | -- | -- | 7.94 | -- | 36.45 | -- | -- | -- |
| Elicera Therapeutics AB | 1.96bn | -3.38bn | 9.26bn | 2.00 | -- | 2.20 | -- | 4.72 | -0.9137 | -0.9137 | 0.5059 | 0.7377 | 0.3224 | -- | 12.85 | 6,035,610.00 | -55.51 | -40.06 | -79.82 | -49.74 | -- | -- | -172.21 | -415.41 | -- | -- | 0.00 | -- | 777.23 | -- | 15.64 | -- | -- | -- |
| Ziccum AB | 902.29m | -3.76bn | 9.32bn | 10.00 | -- | 6.78 | -- | 10.32 | -1.63 | -1.63 | 0.3903 | 0.5312 | 0.2749 | -- | 3.31 | 694,500.00 | -114.67 | -68.51 | -163.12 | -76.47 | -- | -- | -417.19 | -2,598.03 | -- | -- | 0.0654 | -- | -- | 75.20 | 25.62 | -- | -13.45 | -- |
